Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome.

NCT03521063 is registered in ClinicalTrials.gov with Hospital Central "Dr. Ignacio Morones Prieto" as lead sponsor.

NCT NCT03521063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03521063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome.
Lead sponsor
Hospital Central "Dr. Ignacio Morones Prieto"
Phase
Phase 4
Overall status
Unknown status
Start date
January 1, 2018
Completion date
December 31, 2019
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia, infant,premature, respiratory distress syndrome